Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PBI-200 in NTRK-Fusion-Positive Solid Tumors
NCT04901806Phase 1Terminated
- Sponsor
- Pyramid Biosciences
- Start
- Jul 2021
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 1, open-label trial of paltimatrectinib in solid tumor, brain tumor and desmoplastic small round cell tumor (DSRCT) (2 arms), sponsored by Pyramid Biosciences. Primary endpoints: Number of patients with AEs at 36 months, Recommended Phase 2 Dose at 12 months and 1 more. Started Jul 2021; status: terminated.
02
Drugs
paltimatrectinib
03
Conditions
solid tumorbrain tumordesmoplastic small round cell tumor (DSRCT)
Beyond the preview
Go deeper on NCT04901806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04901806.